Silo Pharma provides pipeline update, cites $12M cash and zero debt

Silo Pharma, Inc.

Cash over $12M, no debt, listed on Nasdaq; pursuing 505(b)(2) pathway for several assets.
SP-26 (ketamine for fibromyalgia) preparing pre-IND submission; safety evaluation underway.
SPU-16 (MS) and SPU-21 (RA) under license from University of Maryland; SPU-21 inhibited arthritis in preclinical model.
SPC-14 (Alzheimer's) showed proof-of-concept in mouse model; SPC-15 (PTSD) under Columbia option.
Sponsored clinical study with UCSF on psilocybin's anti-inflammatory effects.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.